Key releases are ad hoc announcements pursuant to SIX Swiss Exchange Art. 53 LR Year None2024 August 13, 2024 Galderma Receives U.S. FDA Approval for Nemluvio® (nemolizumab) for Adult Patients Living With Prurigo Nodularis August 5, 2024 Galderma to pursue a new scientific partnership with L’Oréal to further advance its category leadership in dermatology July 30, 2024 Galderma’s Relfydess™ (RelabotulinumtoxinA) Receives Positive Decision for Use in Europe July 25, 2024 Galderma Delivers Record Net Sales of 2.2 Billion USD and 10.8% Year-on-Year Growth at Constant Currency for the First Half of 2024 April 24, 2024 Galderma Delivers a Strong Start to the Year With Record Net Sales of Over 1 Billion USD for the First Quarter and 12.4% Year-on-Year Growth March 26, 2024 Galderma Announces Full Exercise of Over-Allotment Option